Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RESEARCH TOOLSreports
Holding RXRX?
Track your performance easily
RXRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.60 - $15.74
Previous CloseN/A
Volume5.68M
Average Volume (3M)16.29M
Market Cap
$2.50B
Enterprise Value$1.52B
Total Cash (Recent Filing)$69.88M
Total Debt (Recent Filing)$15.63M
Price to Earnings (P/E)―
Beta3.45
Next Earnings
Mar 04, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding383,723,500
10 Day Avg. Volume15,524,295
30 Day Avg. Volume16,288,809
Standard Deviation0.28
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)28.49
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue23.47
Enterprise Value/Gross Profit1.18K
Enterprise Value/Ebitda-5.83
Forecast
1Y Price Target
$10.33Price Target Upside61.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Recursion Pharmaceuticals News
PremiumCompany Announcements
Recursion Pharmaceuticals Showcases Progress at JP Morgan Conference
PremiumCompany Announcements
Recursion Pharmaceuticals CFO Ben Taylor to Join Exscientia
Bulls Say, Bears Say
Bulls Say
Promising Drug DevelopmentREC-617 shows promising preliminary data with robust target engagement, and further studies are planned to explore combination treatments.
Strategic MergerThe merger with Exscientia enhances Recursion's capabilities by combining a chemical platform for best-in-class programs with a biology-first platform to find novel assets.
Strong Financial PositionRecursion now holds approximately $737M in cash, extending runway into 2027.
Bears Say
Clinical TrialsRXRX shares traded down -9.8% after announcing interim phase 1 ELUCIDATE data for ‘617, Recursion’s CDK7 inhibitor acquired from Exscientia, which looked tolerable on safety, with response/efficacy readouts disappointing albeit early.
Financial PerformanceBrisk cash burn continues to be a concern.
Operational StrategyLong-term risks are associated with pipeline prioritization and deal execution, with concerns over recognizing synergies to minimize cash burn.
---
Ownership Overview
3.93% Insiders
10.86% Mutual Funds
0.08% Other Institutional Investors
64.64% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $5.60 and its highest was $15.74 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Recursion Pharmaceuticals’s market cap is $2.50B.
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.333 by -$0.007.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -0.41.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 383,723,500 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.333. Following the earnings report the stock price went down -0.574%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Among the largest hedge funds holding Recursion Pharmaceuticals’s share is ARK Investment Management LLC. It holds Recursion Pharmaceuticals’s shares valued at 216M.
---
Recursion Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.33 (61.41% Upside)
$10.33 (61.41% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 5.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.52%
12-Months-Change
Fundamentals
Return on Equity
-78.49%
Trailing 12-Months
Asset Growth
15.17%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
---
RXRX Company Deck
---
RXRX Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, focusing on the strategic combination of Recursion and Exscientia to leverage their complementary strengths. The announcement highlighted the potential for significant growth and milestone achievement through their expanded pipeline and partnership network. However, challenges such as clinical trial bottlenecks and integration complexities were acknowledged.Read More>---
RXRX Stock 12 Month Forecast
Average Price Target
$10.33
▲(61.41% Upside)
Technical Analysis
Best Analysts Covering RXRX
1 Year
---